| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Abortion, Induced | 32 | 2025 | 93 | 10.490 |
Why?
|
| Contraception | 18 | 2023 | 60 | 6.850 |
Why?
|
| Pregnancy | 72 | 2025 | 1772 | 4.510 |
Why?
|
| Intrauterine Devices | 9 | 2022 | 19 | 3.580 |
Why?
|
| Contraceptive Agents, Female | 11 | 2022 | 25 | 3.260 |
Why?
|
| Uterine Hemorrhage | 7 | 2020 | 14 | 3.170 |
Why?
|
| Contraception Behavior | 9 | 2020 | 33 | 2.460 |
Why?
|
| Blood Loss, Surgical | 5 | 2018 | 15 | 2.460 |
Why?
|
| Female | 106 | 2025 | 24698 | 2.370 |
Why?
|
| Levonorgestrel | 9 | 2022 | 17 | 2.290 |
Why?
|
| Misoprostol | 10 | 2023 | 27 | 2.160 |
Why?
|
| Intrauterine Devices, Copper | 6 | 2025 | 6 | 2.050 |
Why?
|
| Hawaii | 37 | 2025 | 2011 | 2.040 |
Why?
|
| Humans | 113 | 2025 | 43102 | 1.920 |
Why?
|
| Adult | 64 | 2025 | 13872 | 1.890 |
Why?
|
| Oxytocin | 3 | 2022 | 24 | 1.850 |
Why?
|
| Family Planning Services | 7 | 2022 | 34 | 1.820 |
Why?
|
| Young Adult | 42 | 2025 | 5080 | 1.750 |
Why?
|
| Gestational Age | 11 | 2024 | 200 | 1.670 |
Why?
|
| Pregnancy in Adolescence | 4 | 2016 | 34 | 1.650 |
Why?
|
| Intrauterine Devices, Medicated | 4 | 2020 | 12 | 1.650 |
Why?
|
| Students, Medical | 3 | 2024 | 158 | 1.610 |
Why?
|
| Pregnancy, Unplanned | 8 | 2021 | 29 | 1.490 |
Why?
|
| Sexually Transmitted Diseases | 4 | 2019 | 174 | 1.440 |
Why?
|
| Adolescent | 33 | 2025 | 6081 | 1.420 |
Why?
|
| Contraceptives, Oral, Combined | 6 | 2020 | 12 | 1.360 |
Why?
|
| Obesity | 7 | 2017 | 1151 | 1.340 |
Why?
|
| Ultrasonography, Prenatal | 5 | 2025 | 40 | 1.320 |
Why?
|
| Anticoagulants | 3 | 2017 | 122 | 1.280 |
Why?
|
| Abortifacient Agents | 4 | 2022 | 12 | 1.270 |
Why?
|
| Oxytocics | 3 | 2019 | 8 | 1.260 |
Why?
|
| Analgesics | 2 | 2022 | 55 | 1.260 |
Why?
|
| Cesarean Section | 9 | 2022 | 63 | 1.260 |
Why?
|
| Doxycycline | 4 | 2015 | 32 | 1.250 |
Why?
|
| Delivery, Obstetric | 4 | 2017 | 48 | 1.240 |
Why?
|
| Metrorrhagia | 5 | 2020 | 8 | 1.200 |
Why?
|
| Pregnancy, Ectopic | 3 | 2024 | 15 | 1.180 |
Why?
|
| Health Knowledge, Attitudes, Practice | 8 | 2017 | 989 | 1.130 |
Why?
|
| Postoperative Complications | 3 | 2019 | 263 | 1.100 |
Why?
|
| Retrospective Studies | 23 | 2025 | 2544 | 1.090 |
Why?
|
| Mifepristone | 10 | 2023 | 34 | 1.080 |
Why?
|
| Attitude of Health Personnel | 4 | 2018 | 231 | 1.080 |
Why?
|
| Abortion, Spontaneous | 5 | 2022 | 27 | 1.060 |
Why?
|
| Pain | 2 | 2022 | 290 | 1.030 |
Why?
|
| Pregnancy Outcome | 4 | 2018 | 102 | 1.010 |
Why?
|
| Heparin, Low-Molecular-Weight | 3 | 2017 | 9 | 1.010 |
Why?
|
| Data Collection | 3 | 2019 | 210 | 1.000 |
Why?
|
| Labor, Induced | 2 | 2016 | 4 | 0.970 |
Why?
|
| Body Mass Index | 5 | 2017 | 925 | 0.950 |
Why?
|
| Obstetrics | 6 | 2020 | 43 | 0.940 |
Why?
|
| Dilatation and Curettage | 2 | 2018 | 4 | 0.910 |
Why?
|
| Rh-Hr Blood-Group System | 1 | 2025 | 6 | 0.900 |
Why?
|
| Overweight | 4 | 2017 | 249 | 0.860 |
Why?
|
| Patient Satisfaction | 4 | 2019 | 165 | 0.840 |
Why?
|
| Pharmacy | 2 | 2022 | 34 | 0.830 |
Why?
|
| United States | 21 | 2025 | 5205 | 0.800 |
Why?
|
| Perineum | 2 | 2014 | 9 | 0.790 |
Why?
|
| Contraceptives, Oral, Hormonal | 2 | 2015 | 14 | 0.770 |
Why?
|
| Weight Gain | 2 | 2015 | 139 | 0.760 |
Why?
|
| Women's Health | 3 | 2025 | 160 | 0.760 |
Why?
|
| Double-Blind Method | 9 | 2024 | 317 | 0.750 |
Why?
|
| Health Services Accessibility | 6 | 2022 | 706 | 0.750 |
Why?
|
| Gynecology | 5 | 2018 | 35 | 0.740 |
Why?
|
| Contraception, Postcoital | 2 | 2013 | 8 | 0.730 |
Why?
|
| Pregnancy, Unwanted | 2 | 2021 | 10 | 0.730 |
Why?
|
| Intraoperative Complications | 2 | 2019 | 20 | 0.720 |
Why?
|
| Pharmacists | 1 | 2022 | 61 | 0.720 |
Why?
|
| Postpartum Period | 4 | 2024 | 92 | 0.700 |
Why?
|
| Gonorrhea | 1 | 2021 | 24 | 0.680 |
Why?
|
| Internship and Residency | 3 | 2013 | 146 | 0.660 |
Why?
|
| Contraceptive Agents | 4 | 2022 | 13 | 0.650 |
Why?
|
| Urinary Incontinence | 3 | 2014 | 15 | 0.630 |
Why?
|
| Anti-Bacterial Agents | 2 | 2015 | 432 | 0.620 |
Why?
|
| Abortifacient Agents, Nonsteroidal | 3 | 2018 | 10 | 0.620 |
Why?
|
| Premature Birth | 1 | 2021 | 95 | 0.620 |
Why?
|
| Social Values | 2 | 2016 | 31 | 0.620 |
Why?
|
| Needle-Exchange Programs | 1 | 2019 | 12 | 0.620 |
Why?
|
| Age Factors | 3 | 2018 | 1154 | 0.610 |
Why?
|
| Health Personnel | 2 | 2020 | 277 | 0.610 |
Why?
|
| Sexual Behavior | 4 | 2016 | 638 | 0.610 |
Why?
|
| Chlamydia Infections | 1 | 2021 | 200 | 0.590 |
Why?
|
| Social Control, Formal | 1 | 2018 | 9 | 0.590 |
Why?
|
| Preconception Care | 1 | 2018 | 12 | 0.580 |
Why?
|
| Physicians | 2 | 2020 | 188 | 0.580 |
Why?
|
| Pregnancy Trimester, Second | 3 | 2017 | 15 | 0.580 |
Why?
|
| Communication | 2 | 2017 | 210 | 0.570 |
Why?
|
| Anesthesia, Obstetrical | 2 | 2017 | 8 | 0.560 |
Why?
|
| Hemostatics | 1 | 2018 | 10 | 0.560 |
Why?
|
| Needs Assessment | 1 | 2019 | 178 | 0.550 |
Why?
|
| Intention | 2 | 2024 | 108 | 0.550 |
Why?
|
| Laminaria | 1 | 2017 | 2 | 0.540 |
Why?
|
| Directive Counseling | 1 | 2017 | 16 | 0.540 |
Why?
|
| Dilatation | 1 | 2017 | 4 | 0.530 |
Why?
|
| Pelvic Organ Prolapse | 2 | 2014 | 5 | 0.530 |
Why?
|
| Obstetric Surgical Procedures | 1 | 2017 | 1 | 0.530 |
Why?
|
| Self-Examination | 1 | 2017 | 9 | 0.520 |
Why?
|
| Cross-Sectional Studies | 10 | 2025 | 3156 | 0.520 |
Why?
|
| Telemedicine | 4 | 2021 | 234 | 0.510 |
Why?
|
| Obstetric Labor Complications | 2 | 2014 | 9 | 0.500 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 49 | 0.500 |
Why?
|
| Reproductive Health Services | 1 | 2015 | 15 | 0.470 |
Why?
|
| Trust | 1 | 2017 | 167 | 0.470 |
Why?
|
| Adolescent Health Services | 1 | 2015 | 29 | 0.470 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2015 | 51 | 0.470 |
Why?
|
| Venous Thromboembolism | 1 | 2015 | 22 | 0.460 |
Why?
|
| Pregnancy Complications | 4 | 2015 | 140 | 0.460 |
Why?
|
| Patient Care Planning | 2 | 2017 | 18 | 0.450 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2015 | 95 | 0.450 |
Why?
|
| Endometrium | 1 | 2015 | 59 | 0.440 |
Why?
|
| Tocolysis | 1 | 2014 | 2 | 0.440 |
Why?
|
| Tocolytic Agents | 1 | 2014 | 4 | 0.440 |
Why?
|
| Nifedipine | 1 | 2014 | 10 | 0.440 |
Why?
|
| Tachycardia | 1 | 2014 | 11 | 0.440 |
Why?
|
| Warfarin | 2 | 2017 | 67 | 0.440 |
Why?
|
| Hypotension | 1 | 2014 | 24 | 0.430 |
Why?
|
| Abdomen | 1 | 2014 | 13 | 0.430 |
Why?
|
| Internet | 2 | 2013 | 236 | 0.430 |
Why?
|
| Curriculum | 3 | 2014 | 318 | 0.430 |
Why?
|
| Pressure | 1 | 2014 | 50 | 0.430 |
Why?
|
| Lacerations | 1 | 2014 | 6 | 0.420 |
Why?
|
| Sterilization, Tubal | 2 | 2020 | 6 | 0.420 |
Why?
|
| Ambulatory Care Facilities | 2 | 2011 | 68 | 0.410 |
Why?
|
| Treatment Outcome | 7 | 2024 | 1604 | 0.410 |
Why?
|
| Prospective Studies | 6 | 2024 | 1600 | 0.410 |
Why?
|
| Information Services | 1 | 2013 | 13 | 0.400 |
Why?
|
| Inservice Training | 1 | 2013 | 33 | 0.400 |
Why?
|
| Health Policy | 1 | 2015 | 184 | 0.400 |
Why?
|
| Middle Aged | 13 | 2025 | 12222 | 0.390 |
Why?
|
| Hysteroscopy | 1 | 2012 | 1 | 0.380 |
Why?
|
| Labor Stage, First | 1 | 2012 | 2 | 0.380 |
Why?
|
| Amniotic Fluid | 1 | 2012 | 13 | 0.370 |
Why?
|
| Prenatal Diagnosis | 1 | 2012 | 11 | 0.370 |
Why?
|
| Self Efficacy | 1 | 2013 | 215 | 0.370 |
Why?
|
| Pain Measurement | 4 | 2022 | 183 | 0.360 |
Why?
|
| Progestins | 1 | 2011 | 11 | 0.360 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2011 | 12 | 0.360 |
Why?
|
| Ethinyl Estradiol | 1 | 2011 | 11 | 0.360 |
Why?
|
| Micronesia | 4 | 2018 | 90 | 0.360 |
Why?
|
| Contraceptives, Postcoital | 3 | 2017 | 6 | 0.360 |
Why?
|
| Balloon Occlusion | 1 | 2011 | 3 | 0.350 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2011 | 7 | 0.350 |
Why?
|
| Postnatal Care | 1 | 2011 | 16 | 0.340 |
Why?
|
| Abortifacient Agents, Steroidal | 1 | 2010 | 3 | 0.340 |
Why?
|
| Logistic Models | 6 | 2024 | 1009 | 0.330 |
Why?
|
| Pregnancy Trimester, First | 4 | 2022 | 20 | 0.330 |
Why?
|
| Male | 12 | 2025 | 23409 | 0.330 |
Why?
|
| Ambulatory Care | 1 | 2011 | 81 | 0.320 |
Why?
|
| Pilot Projects | 3 | 2019 | 760 | 0.320 |
Why?
|
| Medical Staff, Hospital | 1 | 2010 | 15 | 0.320 |
Why?
|
| Counseling | 2 | 2023 | 138 | 0.310 |
Why?
|
| Pharmacies | 2 | 2023 | 23 | 0.310 |
Why?
|
| Domestic Violence | 1 | 2009 | 32 | 0.310 |
Why?
|
| Diabetes, Gestational | 1 | 2010 | 56 | 0.300 |
Why?
|
| Headache | 1 | 2009 | 21 | 0.300 |
Why?
|
| Problem-Based Learning | 1 | 2009 | 42 | 0.300 |
Why?
|
| Educational Measurement | 1 | 2009 | 102 | 0.290 |
Why?
|
| Uterine Perforation | 1 | 2008 | 1 | 0.280 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2009 | 95 | 0.280 |
Why?
|
| Health Status | 1 | 2011 | 442 | 0.270 |
Why?
|
| Condoms | 2 | 2019 | 150 | 0.260 |
Why?
|
| Time Factors | 3 | 2019 | 1857 | 0.260 |
Why?
|
| Infant, Newborn | 3 | 2024 | 972 | 0.250 |
Why?
|
| Cervix Uteri | 2 | 2018 | 48 | 0.250 |
Why?
|
| Health Surveys | 3 | 2017 | 405 | 0.240 |
Why?
|
| Education, Medical, Graduate | 2 | 2017 | 61 | 0.230 |
Why?
|
| Ibuprofen | 2 | 2022 | 34 | 0.230 |
Why?
|
| Lidocaine | 2 | 2017 | 16 | 0.230 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2025 | 5 | 0.230 |
Why?
|
| Prevalence | 3 | 2024 | 1612 | 0.230 |
Why?
|
| Mass Screening | 1 | 2009 | 541 | 0.230 |
Why?
|
| Health Priorities | 1 | 2025 | 25 | 0.230 |
Why?
|
| Postal Service | 2 | 2022 | 13 | 0.220 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2005 | 43 | 0.220 |
Why?
|
| Eligibility Determination | 1 | 2024 | 9 | 0.220 |
Why?
|
| Practice Guidelines as Topic | 2 | 2015 | 223 | 0.210 |
Why?
|
| Menstrual Hygiene Products | 1 | 2024 | 1 | 0.210 |
Why?
|
| Intrauterine Device Expulsion | 1 | 2024 | 2 | 0.210 |
Why?
|
| Furosemide | 1 | 2024 | 12 | 0.210 |
Why?
|
| Milk, Human | 1 | 2024 | 51 | 0.210 |
Why?
|
| Diuretics | 1 | 2024 | 51 | 0.210 |
Why?
|
| Attitude to Health | 2 | 2021 | 338 | 0.210 |
Why?
|
| Perception | 2 | 2019 | 215 | 0.200 |
Why?
|
| Sex Education | 2 | 2016 | 36 | 0.200 |
Why?
|
| Forecasting | 1 | 2024 | 136 | 0.200 |
Why?
|
| Adolescent Behavior | 2 | 2016 | 281 | 0.200 |
Why?
|
| Breast Feeding | 1 | 2024 | 126 | 0.190 |
Why?
|
| Analgesics, Opioid | 2 | 2022 | 252 | 0.190 |
Why?
|
| Pharmaceutical Services | 1 | 2023 | 25 | 0.190 |
Why?
|
| Insurance Coverage | 2 | 2020 | 110 | 0.190 |
Why?
|
| Insurance, Health | 1 | 2023 | 145 | 0.190 |
Why?
|
| Birth Weight | 2 | 2015 | 95 | 0.190 |
Why?
|
| Infant | 2 | 2024 | 1175 | 0.190 |
Why?
|
| Labor Pain | 1 | 2022 | 2 | 0.190 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2022 | 3 | 0.190 |
Why?
|
| Fetal Research | 1 | 2022 | 4 | 0.190 |
Why?
|
| Religion | 1 | 2023 | 90 | 0.190 |
Why?
|
| Oxycodone | 1 | 2022 | 7 | 0.190 |
Why?
|
| Fentanyl | 1 | 2022 | 16 | 0.190 |
Why?
|
| Acetaminophen | 1 | 2022 | 30 | 0.180 |
Why?
|
| Odds Ratio | 2 | 2017 | 587 | 0.180 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 1067 | 0.180 |
Why?
|
| Linear Models | 1 | 2023 | 317 | 0.180 |
Why?
|
| Drug Implants | 2 | 2020 | 20 | 0.180 |
Why?
|
| Confidentiality | 2 | 2021 | 29 | 0.180 |
Why?
|
| Antihypertensive Agents | 1 | 2024 | 287 | 0.170 |
Why?
|
| Pregnancy Tests | 1 | 2021 | 1 | 0.170 |
Why?
|
| Chlamydia trachomatis | 1 | 2021 | 70 | 0.170 |
Why?
|
| Desogestrel | 1 | 2020 | 5 | 0.170 |
Why?
|
| Patient Education as Topic | 2 | 2013 | 235 | 0.170 |
Why?
|
| Qualitative Research | 5 | 2023 | 574 | 0.160 |
Why?
|
| Labor, Obstetric | 1 | 2020 | 16 | 0.160 |
Why?
|
| Drug Therapy, Combination | 2 | 2024 | 234 | 0.160 |
Why?
|
| Patient-Centered Care | 2 | 2022 | 75 | 0.160 |
Why?
|
| Tamoxifen | 1 | 2020 | 69 | 0.160 |
Why?
|
| Focus Groups | 2 | 2019 | 423 | 0.160 |
Why?
|
| Norpregnadienes | 2 | 2017 | 4 | 0.150 |
Why?
|
| Foot | 1 | 2019 | 10 | 0.150 |
Why?
|
| Blood Volume | 1 | 2019 | 6 | 0.150 |
Why?
|
| Choice Behavior | 1 | 2020 | 93 | 0.150 |
Why?
|
| Risk Factors | 4 | 2015 | 3994 | 0.140 |
Why?
|
| Methylergonovine | 1 | 2018 | 3 | 0.140 |
Why?
|
| Vasopressins | 1 | 2018 | 12 | 0.140 |
Why?
|
| Colposcopy | 1 | 2018 | 14 | 0.140 |
Why?
|
| Privacy | 1 | 2017 | 7 | 0.140 |
Why?
|
| Sodium Bicarbonate | 1 | 2017 | 7 | 0.130 |
Why?
|
| Obesity, Morbid | 1 | 2017 | 30 | 0.130 |
Why?
|
| Vacuum Extraction, Obstetrical | 1 | 2017 | 5 | 0.130 |
Why?
|
| Blood Transfusion | 1 | 2017 | 31 | 0.130 |
Why?
|
| Parity | 1 | 2017 | 59 | 0.130 |
Why?
|
| Heparin | 1 | 2017 | 40 | 0.130 |
Why?
|
| Clinical Competence | 2 | 2019 | 156 | 0.130 |
Why?
|
| Feasibility Studies | 1 | 2018 | 259 | 0.130 |
Why?
|
| Blood Pressure | 2 | 2024 | 666 | 0.120 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 148 | 0.120 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1063 | 0.120 |
Why?
|
| Reference Values | 2 | 2019 | 211 | 0.120 |
Why?
|
| Tranexamic Acid | 1 | 2015 | 3 | 0.120 |
Why?
|
| Antifibrinolytic Agents | 1 | 2015 | 4 | 0.120 |
Why?
|
| Hormone Antagonists | 1 | 2015 | 13 | 0.120 |
Why?
|
| Professional-Patient Relations | 1 | 2016 | 60 | 0.120 |
Why?
|
| Infant, Low Birth Weight | 1 | 2015 | 36 | 0.120 |
Why?
|
| Complementary Therapies | 1 | 2016 | 51 | 0.120 |
Why?
|
| Chi-Square Distribution | 2 | 2015 | 236 | 0.110 |
Why?
|
| Amnion | 1 | 2015 | 16 | 0.110 |
Why?
|
| Version, Fetal | 1 | 2015 | 3 | 0.110 |
Why?
|
| Breech Presentation | 1 | 2015 | 4 | 0.110 |
Why?
|
| Nerve Block | 1 | 2015 | 5 | 0.110 |
Why?
|
| Analgesia, Obstetrical | 1 | 2015 | 4 | 0.110 |
Why?
|
| Postpartum Hemorrhage | 1 | 2015 | 18 | 0.110 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2015 | 41 | 0.110 |
Why?
|
| Peer Group | 1 | 2016 | 177 | 0.110 |
Why?
|
| Incontinence Pads | 1 | 2014 | 3 | 0.110 |
Why?
|
| Fecal Incontinence | 1 | 2014 | 3 | 0.110 |
Why?
|
| Disposable Equipment | 1 | 2014 | 6 | 0.110 |
Why?
|
| Validation Studies as Topic | 1 | 2014 | 8 | 0.110 |
Why?
|
| Urodynamics | 1 | 2014 | 5 | 0.110 |
Why?
|
| Lifting | 1 | 2014 | 5 | 0.110 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2015 | 54 | 0.110 |
Why?
|
| Patient Simulation | 1 | 2014 | 14 | 0.110 |
Why?
|
| Postoperative Care | 1 | 2014 | 20 | 0.110 |
Why?
|
| Cough | 1 | 2014 | 20 | 0.110 |
Why?
|
| Cohort Studies | 4 | 2023 | 1759 | 0.110 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2015 | 146 | 0.110 |
Why?
|
| Papillomaviridae | 1 | 2015 | 142 | 0.110 |
Why?
|
| Clinical Clerkship | 1 | 2014 | 27 | 0.110 |
Why?
|
| Trauma Severity Indices | 1 | 2014 | 31 | 0.110 |
Why?
|
| Posture | 1 | 2014 | 61 | 0.110 |
Why?
|
| Philippines | 1 | 2014 | 81 | 0.100 |
Why?
|
| Child | 1 | 2022 | 3443 | 0.100 |
Why?
|
| Hysterectomy | 1 | 2013 | 38 | 0.100 |
Why?
|
| Search Engine | 1 | 2013 | 7 | 0.100 |
Why?
|
| Movement | 1 | 2014 | 119 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 179 | 0.100 |
Why?
|
| Robotics | 1 | 2013 | 43 | 0.100 |
Why?
|
| China | 1 | 2014 | 229 | 0.100 |
Why?
|
| Japan | 1 | 2014 | 348 | 0.100 |
Why?
|
| Heart Rate | 1 | 2014 | 266 | 0.100 |
Why?
|
| Parents | 1 | 2016 | 370 | 0.100 |
Why?
|
| Anesthetics, Local | 1 | 2012 | 20 | 0.090 |
Why?
|
| Women | 1 | 2012 | 28 | 0.090 |
Why?
|
| Extraction, Obstetrical | 1 | 2012 | 3 | 0.090 |
Why?
|
| Public Health | 2 | 2020 | 424 | 0.090 |
Why?
|
| Episiotomy | 1 | 2012 | 4 | 0.090 |
Why?
|
| Laparoscopy | 2 | 2013 | 59 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2015 | 863 | 0.090 |
Why?
|
| Access to Information | 1 | 2012 | 15 | 0.090 |
Why?
|
| Vagina | 1 | 2012 | 89 | 0.090 |
Why?
|
| Drug Combinations | 1 | 2011 | 104 | 0.090 |
Why?
|
| Postoperative Hemorrhage | 1 | 2010 | 15 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 440 | 0.080 |
Why?
|
| Body Weight | 1 | 2012 | 429 | 0.080 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 449 | 0.080 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2015 | 367 | 0.080 |
Why?
|
| Interviews as Topic | 2 | 2010 | 452 | 0.080 |
Why?
|
| Hemoglobins | 1 | 2010 | 113 | 0.080 |
Why?
|
| Canada | 2 | 2025 | 163 | 0.080 |
Why?
|
| Maternal Age | 1 | 2010 | 33 | 0.080 |
Why?
|
| Chorioamnionitis | 1 | 2010 | 5 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 153 | 0.080 |
Why?
|
| Private Practice | 1 | 2009 | 2 | 0.080 |
Why?
|
| Teaching Rounds | 1 | 2009 | 4 | 0.080 |
Why?
|
| Program Development | 1 | 2011 | 240 | 0.080 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2009 | 14 | 0.080 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 539 | 0.080 |
Why?
|
| Age Distribution | 1 | 2010 | 249 | 0.080 |
Why?
|
| Migraine Disorders | 1 | 2009 | 9 | 0.080 |
Why?
|
| Patient Compliance | 1 | 2011 | 233 | 0.080 |
Why?
|
| Program Evaluation | 1 | 2011 | 359 | 0.080 |
Why?
|
| Health Status Indicators | 1 | 2009 | 90 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2009 | 107 | 0.070 |
Why?
|
| Patient Participation | 1 | 2010 | 94 | 0.070 |
Why?
|
| Hypertension | 1 | 2015 | 835 | 0.070 |
Why?
|
| Equipment Failure | 1 | 2008 | 12 | 0.070 |
Why?
|
| Quality of Health Care | 1 | 2009 | 161 | 0.070 |
Why?
|
| Device Removal | 1 | 2008 | 7 | 0.070 |
Why?
|
| Intestine, Small | 1 | 2008 | 25 | 0.070 |
Why?
|
| Anxiety | 1 | 2016 | 874 | 0.070 |
Why?
|
| Aged | 3 | 2018 | 8214 | 0.070 |
Why?
|
| Educational Status | 1 | 2009 | 339 | 0.070 |
Why?
|
| Blood Glucose | 1 | 2010 | 389 | 0.070 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 2853 | 0.070 |
Why?
|
| Psychometrics | 1 | 2009 | 358 | 0.070 |
Why?
|
| Case-Control Studies | 1 | 2010 | 1285 | 0.060 |
Why?
|
| Minority Groups | 2 | 2023 | 690 | 0.060 |
Why?
|
| Stroke | 1 | 2009 | 340 | 0.060 |
Why?
|
| Vaginal Smears | 1 | 2005 | 63 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2025 | 135 | 0.060 |
Why?
|
| Health Status Disparities | 1 | 2011 | 719 | 0.050 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2024 | 27 | 0.050 |
Why?
|
| Fetal Tissue Transplantation | 1 | 2022 | 4 | 0.050 |
Why?
|
| Aborted Fetus | 1 | 2022 | 5 | 0.050 |
Why?
|
| Pelvic Pain | 1 | 2022 | 10 | 0.050 |
Why?
|
| Mothers | 1 | 2024 | 215 | 0.050 |
Why?
|
| Abortion, Legal | 1 | 2021 | 6 | 0.040 |
Why?
|
| Drug and Narcotic Control | 1 | 2021 | 12 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 29 | 0.040 |
Why?
|
| Aftercare | 1 | 2021 | 22 | 0.040 |
Why?
|
| Guam | 1 | 2021 | 83 | 0.040 |
Why?
|
| Menstruation | 1 | 2020 | 11 | 0.040 |
Why?
|
| Amenorrhea | 1 | 2020 | 1 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2020 | 368 | 0.040 |
Why?
|
| Self Administration | 1 | 2019 | 69 | 0.040 |
Why?
|
| Medicaid | 1 | 2020 | 143 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2023 | 502 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 341 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2019 | 575 | 0.030 |
Why?
|
| Nonprescription Drugs | 1 | 2017 | 3 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 56 | 0.030 |
Why?
|
| Telephone | 1 | 2017 | 36 | 0.030 |
Why?
|
| Health Expenditures | 1 | 2017 | 44 | 0.030 |
Why?
|
| Decision Making | 1 | 2019 | 249 | 0.030 |
Why?
|
| Sexual Partners | 1 | 2019 | 326 | 0.030 |
Why?
|
| Samoa | 1 | 2015 | 16 | 0.030 |
Why?
|
| Fetal Macrosomia | 1 | 2015 | 12 | 0.030 |
Why?
|
| Family Relations | 1 | 2015 | 46 | 0.030 |
Why?
|
| Anesthesia, Spinal | 1 | 2015 | 2 | 0.030 |
Why?
|
| Anesthesia, Epidural | 1 | 2015 | 3 | 0.030 |
Why?
|
| Analgesia, Epidural | 1 | 2015 | 6 | 0.030 |
Why?
|
| Decision Trees | 1 | 2015 | 22 | 0.030 |
Why?
|
| Cost Savings | 1 | 2015 | 18 | 0.030 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2015 | 18 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2015 | 27 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2015 | 60 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 497 | 0.030 |
Why?
|
| Family Characteristics | 1 | 2015 | 126 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 611 | 0.030 |
Why?
|
| Genital Diseases, Female | 1 | 2013 | 38 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2015 | 363 | 0.020 |
Why?
|
| Social Support | 1 | 2015 | 445 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2012 | 66 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 638 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2010 | 1234 | 0.010 |
Why?
|